Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alcon ( (CH:ALC) ) has provided an update.
On February 24, 2026, Alcon reported its financial results for the quarter and year ended December 31, 2025, highlighting strong topline expansion driven by a wave of new product launches despite softer market conditions. Fourth-quarter 2025 net sales rose 9% year-on-year to $2.7 billion, or 7% in constant currency, with full-year sales up 5% to $10.3 billion, supported by solid growth in both Surgical and Vision Care segments.
Profitability metrics were mixed, as operating margin declined versus 2024 even as core diluted EPS edged higher to $3.07 for 2025, reflecting continued investment alongside efficiency gains. The company generated $2.3 billion in cash from operations and $1.7 billion in free cash flow in 2025, returning $848 million to shareholders via buybacks and dividends, underscoring robust cash generation and a shareholder-friendly capital allocation strategy heading into 2026.
The most recent analyst rating on (CH:ALC) stock is a Buy with a CHF91.00 price target. To see the full list of analyst forecasts on Alcon stock, see the CH:ALC Stock Forecast page.
More about Alcon
Alcon Inc., headquartered in Switzerland and listed on SIX and NYSE under ticker ALC, is a global leader in eye care. The company operates across Surgical and Vision Care segments, selling implantables, consumables, equipment and contact lenses, and focuses on driving growth through innovation in ophthalmic products and procedures worldwide.
Average Trading Volume: 1,096,585
Technical Sentiment Signal: Sell
Current Market Cap: CHF31.5B
Find detailed analytics on ALC stock on TipRanks’ Stock Analysis page.